Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis
Authors:
- 1 August 2016
- journal article
- research article
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 20 (8) , 1065-1071
Abstract
SETTING: Treatment for latent tuberculous infection (LTBI) reduces the risk of tuberculosis (TB) disease. Shorter, rifamycin-containing regimens have been shown to be as effective as 6 months of isoniazid and superior with regard to safety and completion rate. It is unknown whether preventive therapy with rifamycins increases resistance to the drugs used. OBJECTIVE: To determine whether treatment for LTBI with rifamycin-containing regimens leads to significant development of resistance against rifamycins. DESIGN: Systematic review and meta-analysis. RESULTS: We included six randomised-controlled trials of rifamycin-containing regimens for LTBI treatment that reported drug resistance. There was no statistically significant increased risk of rifamycin resistance after LTBI treatment with rifamycin-containing regimens compared to non-rifamycin-containing regimens (RR 3.45, 95%CI 0.72–16.56; P = 0.12) or placebo (RR 0.20, 95%CI 0.02–1.66; P = 0.13). CONCLUSION: Preventive treatment with rifamycin-containing regimens does not significantly increase rifamycin resistance. Programmatic management of LTBI requires the creation of sound surveillance systems to monitor drug resistance.Keywords
This publication has 16 references indexed in Scilit:
- Management of latentMycobacterium tuberculosisinfection: WHO guidelines for low tuberculosis burden countriesEuropean Respiratory Journal, 2015
- LatentMycobacterium tuberculosisInfectionNew England Journal of Medicine, 2015
- New Regimens to Prevent Tuberculosis in Adults with HIV InfectionNew England Journal of Medicine, 2011
- Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutionsAIDS, 2010
- Eliminating latent tuberculosisTrends in Microbiology, 2009
- Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma ConcentrationsAntimicrobial Agents and Chemotherapy, 2008
- Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adultsAIDS, 2001
- Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected PersonsAn International Randomized TrialJAMA, 2000
- Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study.1999
- Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazidThe Lancet, 1999